Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,372 questions · 3,874 findings · 666 reviews

No studies found 431 · 11.1%GRADE not reported 783 · 20.2%Very low 995 · 25.7%Low 909 · 23.5%Moderate 596 · 15.4%High 160 · 4.1%

Low parental socioeconomic status (SES) vs High parental socioeconomic status (SES)

Early childhood caries (ECC) · Healthy children under 6 years in South Africa

No significant difference in caries odds was found between children of low- versus high-SES parents (meta-analysis reported no difference; pooled estimate in an unavailable supplementary figure; not GRADE-rated).

1 finding from 1 review

Lower parental (maternal/paternal) education vs Higher parental education

Dental caries · Healthy children and adolescents in the United Arab Emirates

The association between parental education and caries was inconsistent; father's (but not consistently mother's) education was inversely associated with caries in some studies (narrative synthesis; not GRADE-rated).

1 finding from 1 review

MDA vs no MDA

Parasitaemia prevalence · People of all ages living in an area with moderate to high endemicity of P falciparum malaria (≥ 10% prevalence)

MDA showed no clear difference in parasitaemia prevalence compared with no MDA (low certainty).

1 finding from 1 review

MDA vs no MDA

Parasitaemia incidence · People of all ages living in an area with moderate to high endemicity of P falciparum malaria (≥ 10% prevalence)

MDA probably leads to lower parasitaemia incidence compared with no MDA (moderate certainty).

1 finding from 1 review

MDA vs no MDA

Confirmed malaria illness incidence · People of all ages living in an area with moderate to high endemicity of P falciparum malaria (≥ 10% prevalence)

MDA showed no clear difference in confirmed malaria illness incidence compared with no MDA (low certainty).

1 finding from 1 review

Gemcitabine vs BCG

Time to recurrence · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy

Gemcitabine may leads to lower time to recurrence compared with BCG (low certainty).

1 finding from 1 review

Gemcitabine vs BCG

Time to progression · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy

Gemcitabine may leads to lower time to progression compared with BCG (low certainty).

1 finding from 1 review

Gemcitabine vs BCG

Adverse events grade 3 to 5 Range of · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy

It is very uncertain whether gemcitabine changes grade III–V adverse events compared with BCG (very low certainty).

1 finding from 1 review

Gemcitabine vs BCG

Time to death from bladder cancer · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy

It is very uncertain whether gemcitabine changes time to death from bladder cancer compared with BCG (very low certainty).

1 finding from 1 review

Gemcitabine vs BCG

Time to death from any cause · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine vs BCG

Adverse events: grade 1 to 2 · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy

It is very uncertain whether gemcitabine changes grade I or II adverse events compared with BCG (very low certainty).

1 finding from 1 review

Gemcitabine vs BCG

Disease‐specific quality of life · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy

The review found no eligible studies for this question.

1 finding from 1 review